<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613794</url>
  </required_header>
  <id_info>
    <org_study_id>2011T012</org_study_id>
    <secondary_id>2012-000223-41</secondary_id>
    <nct_id>NCT01613794</nct_id>
  </id_info>
  <brief_title>Rosuvastatin Use to Improve the Coagulation Profile in Patients With Venous Thrombosis</brief_title>
  <acronym>START</acronym>
  <official_title>Prospective Randomized Controlled, Open Label, Clinical Trial to Study if Rosuvastatin Use Improves the Coagulation Profile in Patients With Venous Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Netherlands Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epidemiological studies have shown a 2-3 fold increased long-term risk of arterial
      cardiovascular disease after venous thrombosis, most predominant in the first year following
      initial venous thrombosis. The results of recent observational studies that showed 40-50%
      risk reductions for first venous thrombosis occurrence when using a statin are in this aspect
      promising. The results are also somewhat surprising, because the mechanism behind this effect
      is unclear. Dyslipidemia may be the most plausible explanation to be considered. However, as
      dyslipidemia is not related to an increased risk of venous thrombosis, it is unlikely that
      statins decrease venous thrombosis risk by lipid lowering activities. Recent observations
      indicate that coagulation can activate the initial formation of atherosclerosis. Our
      hypothesis is therefore that the coagulation profile in persons with venous thrombosis is
      improved when using a statin, ultimately leading to less atherosclerosis: another well known
      property of statin use.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coagulation factor VIII</measure>
    <time_frame>28 days</time_frame>
    <description>Change in factor VIII level from baseline to 28 days of intervention</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">255</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>20 mg od</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Persons with (initial or recurrent) confirmed symptomatic proximal deep vein
             thrombosis or pulmonary embolism who after a time period of at least 3 to 12 months
             are allowed to stop, - or stopped using &lt; 1 month anticoagulant treatment as indicated
             by their treating physician

          -  Persons aged 18 years or above

        Exclusion Criteria:

          -  Persons already using statins or lipid lowering drugs, or any other disallowed
             concomitant medications (erythromycin, HIV protease inhibitors, or cyclosporine)

          -  History of statin-induced myopathy, or serious hypersensitivity reaction to other
             HMG-CoA reductase inhibitors (statins), including rosuvastatin

          -  Life expectancy less than 6 months

          -  Pregnant woman or woman with childbearing potential who are not willing to use
             contraception

          -  Active liver or kidney disease or dysfunction or muscle disorders

          -  Unstable medical or psychological condition that interferes with study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Trombosedienst Medial</name>
      <address>
        <city>Hoofddorp</city>
        <state>Zuid Holland</state>
        <zip>2134TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden anticoagulation clinic</name>
      <address>
        <city>Leiden</city>
        <state>Zuid Holland</state>
        <zip>2300RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Lijfering WM, Flinterman LE, Vandenbroucke JP, Rosendaal FR, Cannegieter SC. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. Semin Thromb Hemost. 2011 Nov;37(8):885-96. doi: 10.1055/s-0031-1297367. Epub 2011 Dec 23. Review.</citation>
    <PMID>22198853</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2012</study_first_submitted>
  <study_first_submitted_qc>June 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <last_update_submitted>January 13, 2017</last_update_submitted>
  <last_update_submitted_qc>January 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Willem M. Lijfering</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Deep vein thrombosis</keyword>
  <keyword>Pulmonary embolism</keyword>
  <keyword>Rosuvastatin treatment</keyword>
  <keyword>Pharmacologic actions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

